An observational study in Endometriosis, Complement System and Alternative Complement Pathway, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Ankara City Hospital Bilkent · Observational
Endometriosis is a chronic gynecological condition affecting nearly 10% of women of reproductive age. A definitive diagnosis of endometriosis requires laparoscopy. Studies aim to identify novel biomarkers to aid in the development of effective noninvasive diagnostic methods. Despite several theories, the full understanding of the etiopathogenesis remains elusive. A distorted immune response is thought to play a crucial role in the pathophysiology of endometriosis. This study aimed to evaluate whether the levels of alternative complement molecules change in the blood serum and peritoneal fluid of endometriosis patients compared to healthy subjects.
Endometriosis is a chronic gynecological condition affecting nearly 10% of women of reproductive age. It has been reported to contribute to 21-47% of cases of female infertility and 71-87% of cases involving chronic pelvic pain. The definitive diagnosis of endometriosis requires laparoscopy. While CA-125 has diagnostic value, it is not specific to endometriosis. Therefore, studies are focused on identifying novel biomarkers to aid in the development of effective noninvasive diagnostic methods. Despite numerous theories, the etiopathogenesis of endometriosis remains incompletely understood. A distorted immune response is believed to play a crucial role in the pathophysiology of the condition. Regarding alterations in the classical and lectin-dependent complement systems, C3a, C3c, C4, and C5b-9 have been suggested to hold potential diagnostic value in endometriosis. Alternative pathway is another way for complement activation. This study aimed to investigate whether there are alterations in the levels of alternative complement molecules in both the blood serum and peritoneal fluid of patients diagnosed with endometriosis, comparing these levels to those found in healthy individuals. The research focused on understanding potential differences that could contribute to the pathophysiology of endometriosis, aiming to provide insights into the role of the alternative complement pathway in this gynecological condition.
901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.
This study's enrollment of 58 is below the median of 128 across 344 observational studies indexed under Endometriosis.
Browse Endometriosis studies →Ankara City Hospital Bilkent is the lead sponsor of 424 studies on the registry; 105 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study population includes a total of 58 participants. The study group consists of 32 women with the diagnosis of endometriosis, and the control group consists of 26 healthy women.
Exclusion Criteria:
* The study group included 32 women with endometriosis. * The study group consisted of women diagnosed with endometriosis who consecutively underwent laparoscopic endometriosis surgery.
Diagnostic Test: Mannose-binding lectin-associated serine protease-3 (MASP-3) Level · Diagnostic Test: Adipsin Level · Diagnostic Test: Properdin Level · Diagnostic Test: Complement Factor H (CFH) Level · Diagnostic Test: Cancer Antigen 125 (CA-125) Level
* Control group consisted of 26 healthy women. * The control group consisted of women who consecutively visited the outpatient clinic for routine gynecologic examinations and had no known diseases.
Diagnostic Test: Mannose-binding lectin-associated serine protease-3 (MASP-3) Level · Diagnostic Test: Adipsin Level · Diagnostic Test: Properdin Level · Diagnostic Test: Complement Factor H (CFH) Level · Diagnostic Test: Cancer Antigen 125 (CA-125) Level
Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
Measurement of venous blood serum level of CA-125 level by ELISA method.
Serum and peritoneal fluid mannose-binding lectin-associated serine protease-3 level
Nanogram/milliliter
Time frame: day 1
Serum and peritoneal fluid adipsin level
Nanogram/milliliter
Time frame: day 1
Serum and peritoneal fluid properdin level
Nanogram/milliliter
Time frame: day 1
Serum and peritoneal fluid complement factor H level
Nanogram/milliliter
Time frame: day 1
Serum cancer antigen 125 level
Unit/milliliter
Time frame: day 1
Plan to share: No — IPD are available which may be shared in necessary conditions.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent